GSK Stock Forecast for 2023 - 2025 - 2030
Updated on 05/31/2023
GSK Stock Forecast and Price Target
The average price target of £16.10 for GSK's stock set by sixteen distinguished analysts in recent weeks would represent a potential downside of approximately -98.83% from the last closing price in May, 2023 if reached by the end of the year. This potential increase is based on a high estimate of £25.70 and a low estimate of £11.10. If you are not interested in GSK stock, you may be interested in its competitors.
-98.83% Downside
GSK Fair Value Forecast for 2023 - 2025 - 2030
GSK's Price has decreased In the last two years, from £15.83 to £14.50 – a 8.39% drop. In the next year, analysts believe that Fair Value will reach £15.04 – an increase of 3.71%. For the next nine years, the forecast is for Fair Value to grow by 3.58%.
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| ABBV Stock Forecast | AbbVie | Outperform |
10
|
$136.46 | Buy/Sell | $162.24 | 20.91% |
| AZN Stock Forecast | AstraZeneca PLC | Buy |
8
|
£11.50k | Buy/Sell | £153.20 | -98.64% |
| ABT Stock Forecast | Abbott Laboratories | Outperform |
10
|
$101.73 | Buy/Sell | $122.59 | 22.87% |
| BMY Stock Forecast | Bristol-Myers Squibb Co | Outperform |
2
|
$63.71 | Buy/Sell | $80.99 | 30.28% |
| AMGN Stock Forecast | Amgen Inc | Hold |
7
|
$218.56 | Buy/Sell | $268.00 | 27.20% |
GSK Revenue Forecast for 2023 - 2025 - 2030
In the last two years, GSK's Revenue has grown, rising from £33.75B to £34.11B – a growth of 1.07%. In the following year, 0 experts forecast GSK's Revenue will decrease by 0.36%, to £33.99B. In 2030, professionals predict that GSK's Revenue will decrease by 0.34%, to £34.00B.
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| GILD Stock Forecast | Gilead Sciences Inc | Outperform |
11
|
$76.34 | Buy/Sell | $87.30 | 15.27% |
| CSL Stock Forecast | CSL | Outperform |
8
|
$309.80 | Buy/Sell | $231.47 | -27.03% |
| BDX Stock Forecast | Becton, Dickinson and | Outperform |
17
|
$238.39 | Buy/Sell | $284.07 | 15.36% |
.jpg)
GSK Dividend per Share Forecast for 2023 - 2025 - 2030
In the last two years, GSK's Dividend per Share has seen a drop from £1.00 to £1.00 – a 0.00% decrease. According to 0 major analysts, GSK's Dividend per Share will fall by 0.00% in the next year, reaching £1.00. Professionals believe that By 2030, GSK's Dividend per Share will fall to £1.00– a 0.00% decrease from its current value.
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| CL Stock Forecast | Colgate-Palmolive Co | Outperform |
18
|
$74.95 | Buy/Sell | $81.35 | 9.41% |
| 4568 Stock Forecast | Daiichi Sankyo Company | Outperform |
18
|
¥4.07k | Buy/Sell | ¥0.00 | 35.30% |
| MMM Stock Forecast | 3M Co | Hold |
16
|
$96.07 | Buy/Sell | $147.79 | 24.39% |
GSK Free Cash Flow Forecast for 2023 - 2025 - 2030
In the last two years, GSK's Free Cash Flow has grown by 0.37%, rising from £6.76B to £6.78B. For the next year, analysts predict that Free Cash Flow will reach £6.91B – an increase of 1.94%. Over the next nine years, experts believe that GSK's Free Cash Flow will grow at a rate of 1.98%.
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| BAYN Stock Forecast | Bayer | Outperform |
7
|
53.42€ | Buy/Sell | 74.54€ | 41.33% |
| ABEV3 Stock Forecast | Ambev | Outperform |
18
|
R$14.48 | Buy/Sell | R$17.01 | 19.13% |
| CTVA Stock Forecast | Corteva Inc | Outperform |
12
|
$54.99 | Buy/Sell | $73.12 | 32.75% |
GSK Net Income Forecast for 2023 - 2025 - 2030
In the last two years, GSK's Net Income has gone down from £4.65B to £4.39B – a 5.60% drop. In the next year, analysts believe that Net Income will reach £5.01B – an increase of 14.34%. For the next nine years, the forecast is for Net Income to grow by 15.20%.
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| ADM Stock Forecast | Archer-Daniels-Midland Co | Outperform |
4
|
$71.44 | Buy/Sell | $99.43 | 38.58% |
| 4519 Stock Forecast | Chugai Pharmaceutical | Hold |
18
|
¥3.31k | Buy/Sell | ¥0.00 | 36.03% |
| A Stock Forecast | Agilent Technologies | Outperform |
17
|
$117.75 | Buy/Sell | $162.00 | 41.40% |
GSK EBITDA Forecast for 2023 - 2025 - 2030
In the last two years, GSK's EBITDA has decreased from £10.32B to £9.91B – a 4.03% drop. In the next year, analysts predict that EBITDA will jump to £10.18B – up 2.80% from the current level. Looking ahead to nine years, experts forecast that EBITDA will grow by 2.75%.
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| ALC Stock Forecast | Alcon | Outperform |
15
|
CHF66.18 | Buy/Sell | CHF0.00 | 30.51% |
| BN Stock Forecast | Danone | Hold |
18
|
49.65€ | Buy/Sell | 55.47€ | 11.78% |
| HEN3 Stock Forecast | Henkel AG & Co. KGaA | Hold |
16
|
74.84€ | Buy/Sell | 65.97€ | -11.14% |
GSK EBIT Forecast for 2023 - 2025 - 2030
In the last two years, GSK's EBIT has decreased by 2.87%, going from £8.20B to £7.97B. Analysts predict that GSK's EBIT will increase in the upcoming year, reaching £8.21B. This would represent an increase of 3.00%. Over the next nine years, experts predict that GSK's EBIT will grow at a rate of 2.99%.
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| BEI Stock Forecast | Beiersdorf | Outperform |
17
|
121.15€ | Buy/Sell | 110.36€ | -5.08% |
| COLO B Stock Forecast | Coloplast A/S | Hold |
18
|
kr848.20 | Buy/Sell | kr1.05k | 21.43% |
| 4503 Stock Forecast | Astellas Pharma | Outperform |
18
|
¥1.92k | Buy/Sell | ¥0.00 | 24.74% |
GSK EPS Price Prediction Forecast for 2023 - 2025 - 2030
GSK's EPS has decreased In the last two years, from £1.55 to £1.42 – a 8.39% drop. In the next year, analysts believe that EPS will reach £1.47 – an increase of 3.71%. For the next nine years, the forecast is for EPS to grow by 3.58%.
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| CHD Stock Forecast | Church & Dwight Co Inc | Hold |
11
|
$91.72 | Buy/Sell | $82.17 | -7.33% |
| 4523 Stock Forecast | Eisai | Hold |
18
|
¥8.15k | Buy/Sell | ¥0.00 | -18.99% |
| HOLX Stock Forecast | Hologic Inc | Outperform |
8
|
$84.06 | Buy/Sell | $79.86 | -1.86% |
.jpg)